therapeutic approaches for mg studied in animal models miriam souroujon open university of israel...
TRANSCRIPT
![Page 1: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/1.jpg)
Therapeutic approaches for MG studied in animal models
Miriam Souroujon
Open University of IsraelWeizmann Institute of Science
International Conference on Myasthenia GravisParis, December 2009
![Page 2: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/2.jpg)
Experimental animal models for Myasthenia Gravis
Active immunizationTorpedo AChR
EAMG
Passive transferAnti-AChR Abs
Animal models for MuSK+ MG
Humanized SCID/NOD mouse model for MG
![Page 3: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/3.jpg)
Treatment modalities tested in EAMG
Targeting AChR-specific T and B cell responses•Apheresis of pathogenic anti-AChR antibodies - immunoadsorption on
ECDs• Anti-TCR (Vb5.1) antibodies • Targeting the antigen-binding site of HLA-restricting alleles• Anti-idiotypes (IVIG)
Antigen (AChR)- specific
Immunization by AChR recombinant fragments or synthetic peptides
Denatured AChRSynthetic AChR peptides: Altered peptides, Dominant T cell epitopesAChR recombinant fragments (mucosal tolerance)
Xenogeneic, SyngeneicPathogenic B-cell epitope free
![Page 4: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/4.jpg)
Cell based• Dendritic cells• Mesenchymal stem cells• T regulatory (Treg) cells
Non-cell based targets• Cytokine networks (IFN-g, IL-18, TNF-a, IL-1) • Costimulatory signaling (CD40L) • Complement pathways• Fc receptor• Cholinergic balance at the neuromuscular junction• AChR-associated anchor protein, rapsyn• Chemokines and chemokine receptors (IP-10/CXCR3)• Phosphodiesterases
Treatment modalities tested in EAMGImmunomodulatory approaches
![Page 5: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/5.jpg)
Cell based• Dendritic cells• Mesenchymal stem cells• T regulatory (Treg) cells
Non-cell based targets• Cytokine networks (IFN-g, IL-18, TNF-a, IL-1) • Costimulatory signaling (CD40L) • Complement pathways• Fc receptor• Cholinergic balance at the neuromuscular junction• AChR-associated anchor protein, rapsyn• Chemokines and chemokine receptors (IP-10/CXCR3)• Phosphodiesterases
Treatment modalities tested in EAMGImmunomodulatory approaches
![Page 6: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/6.jpg)
Following PTX treatment
PDE 4
TNF-a, IL-18, IL-12
IL-10
Foxp3
T cell proliferation
Anti-AChR Ab
PDE 1, 4, 7
TNF-a
Cathepsin-l
PDE 2,3,4,7
Cathepsin-l In EAMG PDE 1,3,4,7
Immune systemMuscle
![Page 7: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/7.jpg)
Following PTX treatment
PDE 4
TNF-a, IL-18, IL-12
IL-10
Foxp3
T cell proliferation
Anti-AChR Ab
PDE 1, 4, 7
TNF-a
Cathepsin-l
PDE 2,3,4,7
Cathepsin-l In EAMG PDE 1,3,4,7
Immune systemMuscle
![Page 8: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/8.jpg)
PTX acts as a steroid-sparing agent
![Page 9: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/9.jpg)
PDE4B
Control MG0.0
0.5
1.0
1.5
PDE4D
Control MG0.0
0.5
1.0
1.5
PDE2
Control MG0.0
0.5
1.0
1.5
2.0
2.5
PDE7
Control MG0.0
0.5
1.0
1.5
2.0
2.5
PDE1
Control MG0.0
0.5
1.0
1.5
2.0
2.5
3.0
PDE3
Control MG0.0
0.5
1.0
1.5
2.0
2.5
PDE expression in thymus of MG patients
![Page 10: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/10.jpg)
PDE4B
Control MG0.0
0.5
1.0
1.5
PDE4D
Control MG0.0
0.5
1.0
1.5
2.0
PDE1
Control MG0.0
0.5
1.0
1.5
2.0
2.5
PDE3
Control MG0.0
0.5
1.0
1.5
PDE7
Control MG0.0
0.5
1.0
PDE2
Control MG0.0
0.5
1.0
1.5
2.0
PDE expression in PBL of MG patients
![Page 11: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/11.jpg)
Are phosphodiesterase (PDE) levels altered
in other autoimmune diseases?
• Experimental models ?
• Human diseases ?
![Page 12: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/12.jpg)
*** *** *** **
LNC
*** *** ***
* *
*
0
50
100
150
200
250
PDE1 PDE2 PDE3 PDE4 PDE7 TNF-a
Gen
e/A
ctin
(%
)
CFA
EAE
0
50
100
150
200
250
PDE1 PDE2 PDE3 PDE4 PDE7 TNF-a
Gen
e/A
ctin
(%
)
CFA
EAE
CD4+ cells
*
*
*
******
***
![Page 13: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/13.jpg)
PDE expression in PBL of Multiple Sclerosis patients
PDE1
CONTROL MS
0.0
0.2
0.4
0.6
0.8
1.0
1.2
PDE3
CONTROL MS
0
10
20
30
40
50
PDE7
CONTROL MS
0
1
2
3
4
5
6
PDE4B
CONTROL MS
0.0
0.5
1.0
1.5
2.0
PDE4D
CONTROL MS
0
1
2
3
![Page 14: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/14.jpg)
• The expression levels of selective PDE subtypes are upregulated in EAMG and MG.
• The general PDE inhibitor PTX acts as a steroid sparing agent in EAMG.
• The expression levels of selective PDE subtypes are upregulated also in multiple sclerosis (MS) and its animal model, EAE.
• PDEs may be potential therapeutic targets in various autoimmune diseases.
Summary IPDE
![Page 15: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/15.jpg)
Cell based• Dendritic cells• Mesenchymal stem cells• T regulatory (Treg) cells
Non-cell based targets• Cytokine networks (IFN-g, IL-18, TNF-a, IL-1) • Costimulatory signaling (CD40L) • Complement pathways• Fc receptor• Cholinergic balance at the neuromuscular junction• AChR-associated anchor protein, rapsyn• Chemokines and chemokine receptors (IP-10/CXCR3)• Phosphodiesterases
Treatment modalities tested in EAMGImmunomodulatory approaches
![Page 16: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/16.jpg)
Treg abnormalities are observed in MG
• Functional impairments were found in thymic Treg cells of MG patients
• Decreased CD4+CD25high cell numbers were found in PBL of MG patients
• Successful treatments or thymectomy result in elevated numbers of CD4+CD25high cells
• CD4+CD25+ cells are involved in the suppressive action of various effective therapies in EAMG
![Page 17: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/17.jpg)
EAMG rats have reduced levels of Treg cells
AChR CFA Naive
123456789
p<0.05
AChR CFA Naive
1
2
3
4
5
6p<0.05
AChR CFA Naive
1.00
1.25
1.50
1.75
2.00
p<0.01
![Page 18: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/18.jpg)
Treg-based treatments
CancerInfectious disease Autoimmune
Inflammatory disease
• Administration of Exogenous Treg
• Modulation of endogenous Treg
Treg
![Page 19: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/19.jpg)
Ex-vivo generation of CD4+CD25+ regulatory T cells
Spleen from healthy or EAMG donor rat
Negative selection of CD4+ cells using magnetic beads
Y Y
Y Y
Y
Y
Y Y
YYY
Y
Y
YYY
Y YY
90%
CD
4
+ TGF- ,b IL-2
culture cells on anti-CD3 and
anti-CD28 coated plates
![Page 20: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/20.jpg)
Characterization of ex vivo generated CD4+CD25+ Treg cells
5%
CD
4
CD25
EAMG Splenocytes + + + + Co-culture with - evCD4+CD25+
nCD4+CD25+ nCD4+CD25-
0
1000
2000
3000
4000
5000
6000
CP
M
* *
96%
DAY 0 DAY 3
Foxp3
0
0.1
0.2
0.3
0.4
0.5
evCD4+CD25+ nCD4+CD25-Rel
ativ
e ex
pre
ssio
n l
evel
s
CTLA-4
0
0.5
1
1.5
2
2.5
3
3.5
evCD4+CD25+ nCD4+CD25-Rel
ati
ve
ex
pre
ss
ion
le
vel
s
TGF- b
0
0.5
1
1.5
evCD4+CD25+ nCD4+CD25-Rel
ativ
e ex
pre
ssio
n l
evel
s
![Page 21: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/21.jpg)
Treg generated ex vivo from healthy donors suppress EAMG
0 1 2 3 4 5 6 7 80.0
0.5
1.0
1.5
2.0
2.5 PBS
evCD4+CD25+
nCD4+CD25-
Weeks
0 1 2 3 4 5 6 7 80
20
40
60
80
100
Weeks
![Page 22: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/22.jpg)
CD25
Healthy
EAMG
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 2 3 4 5 6 7 8 9 10 11 12
Weeks
Clin
ical score
evCD4+CD25+ from EAMG donors
CONTROL (PBS)
evCD4+CD25+ from healthy donors
Treg from myasthenic rats exacerbate EAMG
![Page 23: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/23.jpg)
Revisiting the Th1-Th2 Paradigm
Naive T cell
Dendritic cell
TGF-
IFN IL-4 + IL-6 - IL-6
Th1Tbet
Th2Gata 3
Th17RORT
TregFoxp3
IL-12R
IL-12
IL-23R
IL-23
Adapted from Reiner et al., Cell, 2007
Autoimmunity Inflammation Cancer
Extracellular bacteria
Allergy and asthma
Systemic pathology
Harmful role
Counter regulation
Parasitic worms
Intracellular pathogens
Protective role
![Page 24: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/24.jpg)
Naive CFA EAMG
0
1
2
3
Naive CFA EAMG
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
3 Weeks 7 Weeks
Expression of Foxp3
![Page 25: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/25.jpg)
IL-23
Naive CFA EAMG
0.0
0.3
0.6
0.9
1.2
1.5
1.8 *IL-23
Naive CFA EAMG
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
IL-23R
Naive CFA EAMG
0
1
2
3
IL-23R
Naive CFA EAMG
0.0
0.5
1.0
1.5
2.0 *
IL-17
Naive CFA EAMG
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5*
IL-17
Naive CFA EAMG
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
IL-17R
Naive CFA EAMG
0.00.10.20.30.40.50.60.70.80.91.01.1
IL-17R
Naive CFA EAMG
0.00
0.25
0.50
0.75 *
3 Weeks 7 Weeks
Expressionof Th17-relatedgenes
![Page 26: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/26.jpg)
TGF-
Naive CFA EAMG
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
*
TGF-
Naive CFA EAMG
0.3
0.4
0.5
0.6
0.7
0.8
0.9
IL-6
Naive CFA EAMG
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
IL-6
Naive CFA EAMG
0.0
0.1
0.2
0.3 *
IL-6R
Naive CFA EAMG
0.6
0.8
1.0
1.2
1.4
1.6
IL-6R
Naive CFA EAMG
0.45
0.65
0.85
1.05
*
3 Weeks 7 Weeks
Expressionof regulatory
cytokines
![Page 27: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/27.jpg)
Treatment by anti-IL-6 Abs starting at the acute phase of EAMG
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 2 3 4 5 6 7 8 9 10
weeks
clin
ical score
PBSanti IL-6
![Page 28: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/28.jpg)
0
0.5
1
1.5
2
2.5
3
3.5
4
0 1 2 3 4 5 6 7 8 9 10 11
weeks
clin
ical score
anti IgG
anti IL-6
Treatment by anti-IL-6 Abs starting at the chronic phase of EAMG
![Page 29: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/29.jpg)
*
Total anti-AChR IgG
control anti IL-6
0.0
0.1
0.2
0.3
control anti IL-6
0
10
20
30
40
% of splenic B cells
*
![Page 30: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/30.jpg)
Expression following anti-IL-6 treatment
Foxp3
Control Anti-IL-60
1
2
3
IL-6
Control Anti-IL-60
1
2
3
IL-6R
Control Anti-IL-60.0
0.5
1.0
1.5
2.0
2.5
![Page 31: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/31.jpg)
Cytokines expression following anti IL-6 treatment
IL-17A
Control Anti-IL-60
1
2
3
4
5
6
7
8
9
IL-17R
Control Anti-IL-60.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
IL-21
Control Anti-IL-60
1
2
3
4
IL-23
Control Anti-IL-60.0
0.5
1.0
1.5
2.0
IL-23R
Control Anti-IL-6
0
1
2
3
4
TGF-
Control Anti-IL-60.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
![Page 32: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/32.jpg)
Serum IL-17 in anti-IL-6 treated rats
control Anti-IL-6
0
1
2
3
4
5
6
![Page 33: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/33.jpg)
Revisiting the Th1-Th2 Paradigm
Naive T cell
Dendritic cell
TGF-
IFN IL-4 + IL-6 - IL-6
Th1Tbet
Th2Gata 3
Th17RORT
TregFoxp3
IL-12R
IL-12
IL-23R
IL-23
Adapted from Reiner et al., Cell, 2007
Autoimmunity Inflammation Cancer
Extracellular bacteria
Allergy and asthma
Systemic pathology
Harmful role
Counter regulation
Parasitic worms
Intracellular pathogens
Protective role
![Page 34: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/34.jpg)
Summary II
Treg
Suppression of EAMG can be achieved by:
¨ Administration of exogenous Treg from healthy donors
¨ Shifting the balance between endogenous Treg and Th17 in favor of Treg
![Page 35: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/35.jpg)
Hopefully, the vast repertoire of therapeutic approaches studied in experimental models of MG will pave the way to clinical studies
that will eventually improve the management of MG
![Page 36: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/36.jpg)
Thanks !!Thanks !!
• Sara Fuchs• Revital Aricha• Tali Feferman• Keren Mizrachi
• Sonia Berrih-Aknin
• Ariel Miller (MS)• Avi Ben-Nun (EAE)
• Sara Fuchs• Revital Aricha• Tali Feferman• Keren Mizrachi
• Sonia Berrih-Aknin
• Ariel Miller (MS)• Avi Ben-Nun (EAE)
![Page 37: Therapeutic approaches for MG studied in animal models Miriam Souroujon Open University of Israel Weizmann Institute of Science International Conference](https://reader030.vdocuments.mx/reader030/viewer/2022032723/56649d0a5503460f949dc188/html5/thumbnails/37.jpg)
Recipients of Treg have elevated CD4+CD25+FoxP3+ cells
FoxP3+
PBS treated
31%
FoxP3+
54%
evCD4+CD25+ treated
0
1
2
3
4
PBS nCD4+CD25- evCD4+CD25+
% o
f C
D25
+am
on
g C
D4+
cel
ls
*
0
1
2
3
PBS nCD4+CD25- evCD4+CD25+% o
f C
D25
+F
oxP
3+am
on
g C
D4+
ce
lls
% F
oxP
3+ am
on
g C
D4+
CD
25+ cells o
f recipien
ts